Recommendation of the President – Sialanar (glycopyrronium bromide)

On 20 May 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 69/2026 on the inclusion of the medicinal product Sialanar (glycopyrronium bromide) in the reimbursement program for the following indication: symptomatic treatment of severe sialorrhea (chronic pathological salivation) in children and adolescents aged 3 years and older with cerebral palsy

Publication in Public Information Bulletin (BIP) >>